AlenCiken

Positive Primary Efficacy Data+Positive Preclinical Outcomes

NASDAQ:VIVE   None
Viveve Announces Positive Primary Efficacy Data from its SUI Feasibility Study and Positive Preclinical Outcomes that Support the Company’s New Sham Tip for Pivotal PURSUIT Trial

Achievement of primary efficacy endpoint in 3-arm SUI feasibility study demonstrates significant separation between CMRF treatment arm and inert sham arm
Positive in-vivo preclinical study validates new inert sham tip for use in upcoming pivotal PURSUIT Trial in U.S.

finance.yahoo.com/ne...icacy-100200629.html

면책사항

이 정보와 게시물은 TradingView에서 제공하거나 보증하는 금융, 투자, 거래 또는 기타 유형의 조언이나 권고 사항을 의미하거나 구성하지 않습니다. 자세한 내용은 이용 약관을 참고하세요.